AKLI | Akili, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.4300 - 0.4331
52 Week Range	0.1912 - 1.2500
Beta	3.39
Implied Volatility	333.75%
IV Rank	99.31%
Day's Volume	236,452
Average Volume	2,299,004
Shares Outstanding	78,726,704
Market Cap	34,096,536
Sector	Healthcare
Industry	Medical - Healthcare Information Services
IPO Date	2021-06-30

Valuation
Profitability
Growth
Health
P/E Ratio	-0.71
Forward P/E Ratio	N/A
EPS	-0.61
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	68
Country	USA
Website	AKLI

Akili, Inc., a digital medicine company, develops digital therapeutics for cognitive impairments. It provides EndeavorRx, a physician-prescribed video game-based treatment designed to directly target cognitive functioning. The company is based in Boston, Massachusetts.

AKLI's peers: RNLX, SY, ZCMD, ACON, EUDA, WGS, MGRX

*Chart delayed

Analyzing fundamentals for AKLI we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is very bad and Health is weak. For more detailed analysis please see AKLI Fundamentals page.

Watching at AKLI technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on AKLI Technicals page.